Highlights from the ESMO Annual Meeting 2023–EORTC GI Tract Group picks from the colorectal and anal cancer track

摘要: The only potentially practice-changing study was CodeBreaK 300. This can be considered as the (hopefully first) happy ending of a story that started w1 decade ago when, after being long considered undruggable, KRAS has eventually turned into a therapeutic target with the development of KRASG12C inhibitors. Based on the promising results from prior studies, CodeBreaK 300 tested the superiority of combined KRAS and epidermal growth factor receptor (EGFR) inhibition over standard-of-care treatment. 1 In this randomised three-arm phase III trial, 160 patients with chemorefractory KRASG12C-mutated colorectal cancer (CRC) were treated with high-dose (960 mg daily) sotorasib plus panitumumab, low-dose (240 mg daily) sotorasib plus panitumumab, or standard treatment according to the investigator’s choice (trifluridine/tipiracil or regorafenib). The primary endpoint was progression-free survival (PFS) by …